|Articles|April 1, 1996

Osteoarthritis
Volume 2
Issue 6 Suppl

Development of an Economic Model Comparing Acetaminophen to NSAIDs in the Treatment of Mild-to-Moderate Osteoarthritis

Author(s)Susan Sedory Holzer, MA, Timothy Cuerdon, PhD

Download PDF: Development of an Economic Model Comparing Acetaminophen to NSAIDs in the Treatment of Mild-to-Moderate Osteoarthritis

Articles in this issue

over 30 years ago

Article

Use of Clinical Guidelines for Improvement of Quality of Care

over 30 years ago

Article

Guidelines for the Management of Osteoarthritis of the Hip and Knee

over 30 years ago

Article

Management of Osteoarthritis in the Managed Care Setting

over 30 years ago

Article

CME Quiz

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

Development of an Economic Model Comparing Acetaminophen to NSAIDs in the Treatment of Mild-to-Moderate Osteoarthritis

Articles in this issue

Related Content

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

Trending on AJMC

FAQs: FDA Lawsuit Challenges E-Cigarette Enforcement Policy, PMTA Guidance

Tec-Dara Closes Survival Gap in High-Risk MM: Rahul Banerjee, MD

Cognitive Rehabilitation Improves Functional Outcomes in Long COVID Brain Fog

PMOS Linked to 4-Fold Atherosclerotic Heart Disease Risk in 2.5 Million US Women

CAR T-Cell Therapy Shows Promise in Refractory Myasthenia Gravis, Evidence Still Limited